Loading
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Latest quote
$6.25
−$0.16 · -2.50%
After-hours
$6.25
$0.00 · 0.00%
Oct 9, 4:00 PM ET
Regular session · ET · Market data may be delayed.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Day range
Current $6.25
52-week range
Current $6.25
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
56
Mixed
Risk
67
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Day range
Current $6.25
52-week range
Current $6.25
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 13M USD | 7M USD | 5M USD |
| Cost of goods sold | — | 1.29M USD | 1M USD |
| Gross profit | 13M USD | 5.71M USD | 4M USD |
| Research and development | 74.04M USD | 64.24M USD | 32M USD |
| Selling, general, and administrative | 20.03M USD | 11.48M USD | 9.85M USD |
| Operating expenses | 94.07M USD | 75.73M USD | 41.85M USD |
| Interest income | 3.32M USD | 3.24M USD | 3.86M USD |
| Interest expense | — | 34K USD | 58K USD |
| Depreciation and amortization | 1.39M USD | 1.29M USD | 1M USD |
| Operating income | −81.07M USD | −70.01M USD | −37.85M USD |
| Net income | −68.87M USD | −66.81M USD | −34.05M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI9.36M0.00%2.3T USD0.03%$381.92+0.62%
iShares Russell 2000 ETFIWM2.54M0.00%77.7B USD0.19%$278.93+0.49%
Vanguard Extended Market ETFVXF1.6M0.00%95.4B USD0.05%$235.04+0.82%
Fidelity Enhanced Small Cap ETFFESM941.63K0.01%6.41B USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO923.75K0.01%18B USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO919.74K0.01%14.04B USD0.24%$356.67+0.91%
Schwab U.S. Small-Cap ETFSCHA707.2K0.00%21.73B USD0.03%$32.795+0.41%
Vanguard Health Care ETFVHT370.01K0.00%22B USD0.09%$319.03+1.65%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
